Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Misghina Weldegiorgis
  • Dick de Zeeuw
  • Liang Li
  • Hans-Henrik Parving
  • Fan Fan Hou
  • Giuseppe Remuzzi
  • Tom Greene
  • Hiddo J L Heerspink
Vis graf over relationer

BACKGROUND: In clinical practice and clinical trials, changes in serum creatinine concentrations are used to evaluate changes in kidney function. It has been assumed that these changes follow a linear pattern when serum creatinine concentration is converted to estimated glomerular filtration rate (eGFR). However, the paradigm that kidney function declines linearly over time has been questioned by studies showing either linear or nonlinear patterns. To verify how this impacts on kidney end points in intervention trials, we analyzed eGFR trajectories in multiple clinical trials of patients with and without diabetes.

STUDY DESIGN: Longitudinal observational study.

SETTING & PARTICIPANTS: 6 clinical trials with repeated measurements of serum creatinine.

PREDICTOR: Patient demographic and clinical parameters.

OUTCOMES: Probability of nonlinear eGFR function trajectory calculated for each patient from a Bayesian model of individual eGFR trajectories.

RESULTS: The median probability of a nonlinear eGFR decline in all trials was 0.26 (interquartile range, 0.13-0.48). The median probability was 0.28 in diabetes versus 0.09 in nondiabetes trials (P<0.01). The percentage of patients with a >50% probability of nonlinear eGFR decline was generally low, ranging from 19.3% to 31.7% in the diabetes trials and from 15.1% to 21.2% in the nondiabetes trials. In the pooled data set, multivariable linear regression showed that higher baseline eGFR, male sex, diabetes status, steeper eGFR slope, and non-renin-angiotensin-aldosterone-system antihypertensives were independently associated with a greater probability of a nonlinear eGFR trajectory.

LIMITATIONS: Relatively short follow-up and no measured GFR.

CONCLUSIONS: In both diabetes and nondiabetes trials, the majority of patients show a more or less linear eGFR decline. These data support the paradigm that in diabetic and nondiabetic kidney disease, eGFR decline progresses linearly over time during a clinical trial period. However, in diabetes, one should take the nonlinearity proportion into account in the design of a clinical trial.

TidsskriftAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
Udgave nummer1
Sider (fra-til)91-101
Antal sider11
StatusUdgivet - jan. 2017

ID: 52659454